Cytokinetics Announces Positive ACACIA-HCM Results for Aficamten

Cytokinetics met primary endpoints in the ACACIA-HCM Phase 3 trial, demonstrating statistically significant improvements in patient-reported outcomes and exercise performance for non-obstructive HCM, leading to a planned supplemental NDA submission to the FDA.